Contract Development & Manufacturing

GlycoNex provides contract development and manufacturing (CDMO) services for antibody and antibody-based therapeutics, drawing on the same integrated organization that develops its own clinical-stage ADCs and biosimilars. Capabilities span cell line development; upstream, midstream, and downstream process development and optimization; scale-up; GMP manufacturing; and technology transfer. Manufacturing is supported by GMP-compliant antibody production at 50-liter intermediate and 200-liter production scale at the company's New Taipei City facility, capable of supplying Phase 1 clinical material. Contract development and manufacturing services form a deliberate part of GlycoNex's business model, providing a recurring revenue stream alongside its proprietary drug development programs.

Glycosylation is a defining quality attribute for antibody therapeutics — and the area where GlycoNex's glycan-science heritage runs deepest. Our in-house laboratory resolves glycan structure, glycoform composition, and lot-to-lot consistency in detail, as one part of a complete characterization panel that spans identity, purity and charge, potency, primary and higher-order structure, and impurity and safety testing. For biosimilar programs, glycoform composition and consistency are central comparability attributes; for novel antibodies and ADCs, the same analytical depth ties process development directly to product quality.

In December 2025, GlycoNex entered a contract development and manufacturing agreement with Change Cure, a spin-off from Institute of Science Tokyo, for CC001 — an HMGB1-targeted antibody program for frontotemporal lobar degeneration (FTLD), a neurodegenerative indication. GlycoNex also provides contract services to additional biotechnology companies in Taiwan whose engagements remain confidential.